Zacks: Brokerages Expect ADMA Biologics Inc (ADMA) to Announce -$0.55 EPS
Equities analysts expect that ADMA Biologics Inc (NASDAQ:ADMA) will announce ($0.55) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.70) to ($0.39). ADMA Biologics posted earnings of ($0.35) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 57.1%. The firm is scheduled to issue its next quarterly earnings results on Friday, February 23rd.
According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($2.25) per share for the current year, with EPS estimates ranging from ($2.73) to ($1.66). For the next year, analysts expect that the company will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.25) to ($1.41). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover ADMA Biologics.
ADMA has been the topic of several research analyst reports. Raymond James Financial, Inc. raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
In other ADMA Biologics news, insider Adam S. Grossman acquired 485,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The shares were acquired at an average cost of $2.15 per share, with a total value of $1,042,750.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was acquired at an average cost of $2.15 per share, for a total transaction of $53,750.00. Following the completion of the acquisition, the director now directly owns 31,300 shares in the company, valued at $67,295. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 526,500 shares of company stock worth $1,131,975. 60.44% of the stock is owned by insiders.
Shares of ADMA Biologics (ADMA) opened at $2.75 on Wednesday. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $6.47. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.